Chemical Name:2-[2-METHOXY-4-(METHYLSULFINYL)PHENYL]-1H-IMIDAZO[4,5-B]PYRIDINE
- CAS No.73384-60-8
- Molecular Formula:C14H13N3O2S
- Formula Weight:287.342
Synonyms:1H-Imidazo[4,5-b]pyridine,2-[2-methoxy-4-(methylsulfinyl)phenyl]- (9CI); 115BS; AR-L; AR-L 115; AR-L115BS; Sulmazole; Vardax
*The following content is generated by AI and is for reference only.
Sulmazole, chemically designated as 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-b]pyridine, is a potent and selective cardiac myosin activator widely utilized in pharmaceutical research and development. With the CAS Registry Number 73384-60-8, this compound represents a significant advancement in the field of cardiology, offering a unique mechanism of action distinct from traditional beta-adrenergic agonists or phosphodiesterase inhibitors. The molecular formula for Sulmazole is C14H15N3O2S, reflecting its complex heterocyclic structure which includes an imidazopyridine core substituted with a methoxy group and a methylsulfinyl moiety. This specific chemical architecture allows it to enhance myocardial contractility by increasing the sensitivity of cardiac myofibrils to calcium ions, thereby improving the force of heart muscle contraction without significantly altering intracellular calcium levels or heart rate.
In the global pharmaceutical market, high-purity Sulmazole (often available at 99% purity under Good Manufacturing Practice standards) serves as a critical reference standard and active pharmaceutical ingredient (API) intermediate. Its primary application lies in the investigation and treatment of congestive heart failure, where it aims to improve hemodynamic parameters and exercise tolerance. Unlike catecholamines that increase oxygen demand and arrhythmia risk, Sulmazole offers a potentially safer profile by directly targeting the contractile machinery. Consequently, it is extensively used in preclinical studies to evaluate novel therapeutic strategies for systolic dysfunction. Researchers utilize Sulmazole to understand the pathophysiology of heart failure and to screen potential drug candidates that modulate cardiac performance. Furthermore, its stability and solubility characteristics make it suitable for various in vitro and in vivo experimental models. As regulatory agencies continue to emphasize rigorous quality control, suppliers provide Sulmazole with comprehensive Drug Master Files (DMF), ensuring compliance with international safety and efficacy standards for clinical trials and commercial production. This compound remains a cornerstone molecule in cardiovascular pharmacology, bridging the gap between basic biochemical research and clinical therapeutic applications for millions of patients suffering from compromised cardiac function.
![99% up GMP DMF Sulmazole 2-[2-METHOXY-4-(METHYLSULFINYL)PHENYL]-1H-IMIDAZO[4,5-B]PYRIDINE 73384-60-8](https://eimg.pharmasources.com/image/20211122/yEVbIgyOWpn2ohNePISQIqjQQok4DnJvi4x1syKM.jpeg)
(All Rights Reserved)
